PDCD1 and cancer: As PD-1/PD-L1 inhibitors have been rapidly integrated into standard of care for NSCLC and increasing numbers of other cancer types [34–38], more mechanistic studies are needed to understand the underlying mechanisms of tumor response and resistance.